News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|September 17, 2024

Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact

Author(s)Ryan Haumschild, PharmD, MS, MBA, James McCloskey, MD , Amer Zeidan, MD

Medical experts discuss innovations and future directions in treatments for higher-risk MDSMedical experts offer patient perspectives on advantages and disadvantages of using oral HMAs vs injectable HMAs.

Episodes in this series

EP. 1 Advances in MDS Classification and Molecular Understanding

EP. 1 Advances in MDS Classification and Molecular Understanding

EP. 2 Choosing MDS Therapies: Risk-Based Approaches

EP. 2 Choosing MDS Therapies: Risk-Based Approaches

EP. 3 Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial

EP. 3 Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial

EP. 4 ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS

EP. 4 ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS

EP. 5 Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS

EP. 5 Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS

EP. 6 HMA Persistence and Effectiveness in Higher Risk MDS

EP. 6 HMA Persistence and Effectiveness in Higher Risk MDS

EP. 7 Innovations and Future Directions in Higher Risk MDS Treatments

EP. 7 Innovations and Future Directions in Higher Risk MDS Treatments

EP. 8 Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact

EP. 8 Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact

EP. 9 Oral vs. IV HMAs: Considerations and Patient Guidance

EP. 9 Oral vs. IV HMAs: Considerations and Patient Guidance

EP. 10 Patient Feedback for MDS: Insights and Closing Remarks

EP. 10 Patient Feedback for MDS: Insights and Closing Remarks

Video content above is prompted by the following:

From a patient’s perspective, what are some of the advantages and disadvantages of using oral hypomethylating agents (HMAs) vs injectable HMAs?
How do you anticipate the Inflation Reduction Act’s out-of-pocket prescription drug cost cap will affect access to oral HMAs starting in 2025?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

Trump Childhood Vaccine Order: What It Means for Parents and Payers

Cardiac Amyloidosis Diagnosis Lags After Heart Failure Onset

Payer Barriers and Anatomic Urgency in Vitiligo Treatment

Classifying Vitiligo Severity Beyond Body Surface Area